Studies Link Bayer Drug Trasylol To Patient Deaths

Boston (dbTechno) - Two new U.S. studies have linked the Bayer AG drug Trasylol to numerous deaths of patients. Bayer AG stopped selling the drug last fall after the deaths took place. It has now been confirmed that the drug, which was an anti-bleeding drug used on heart surgery patients, increased their risk of death.

Trasylol was found in the study to increase the risk of death in heart surgery patients given the drug.

The first of two studies looked at over 10,000 patients who had to go through heart surgeries.

They found that 6.4% of the patients who were given the drug Trasylol died within 30 days of the surgery.

Compared to patients who receievd a different drug, or no drug at all for their bleeding, the death risk for those who took Trasylol was 2.5 times higher.

A second study, which was actually funded by Bayer, found that out of a group of 78,000 patients, the risk of death following surgery was 64% higher in the group that took the drug Trasylol.

Bayer has yet to agree with the two studies which are in the New England Journal of Medicine. The drug has been blamed though for thousnands upon thousands of deaths, as it is clear from these two studies anyways, flawed or not, that it increases the mortality risk for patients.